Meeting
2014 ASCO Annual Meeting
Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial.
Authors
Jaime Feliu
Medical Oncology Department. La Paz University Hospital, Madrid, Spain
Jaime Feliu , Rocio Garcia-Carbonero , Jaume Capdevila , Inmaculada Guasch , Vicente Alonso , Carlos Lopez , Pilar Garcia-Alfonso , Carmen Castañon , Laura Cerezo , Isabel Sevilla , Carles Conill , Begona Quintana-Angel , Maria Elena Sanchez , Jose Lopez-Torrcilla , Ismael Ghanem , Juan Maurel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Anal Cancer
Clinical Trial Registration Number
NCT01285778
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4034)
DOI
10.1200/jco.2014.32.15_suppl.4034
Abstract #
4034
Poster Bd #
121
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.
First Author: Jaime Feliu
Poster
2012 ASCO Annual Meeting
Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.
First Author: Madhur Garg
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
First Author: Naoki Furuya